154 related articles for article (PubMed ID: 7716641)
1. [Immunohistochemical analysis of malignant tumors of the thyroid gland using 6 relevant markers].
Brasanac D; Jancić-Zgurics M; Janković R; Tatić S
Srp Arh Celok Lek; 1993; 121(3-7):70-3. PubMed ID: 7716641
[TBL] [Abstract][Full Text] [Related]
2. Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms.
Inohara H; Honjo Y; Yoshii T; Akahani S; Yoshida J; Hattori K; Okamoto S; Sawada T; Raz A; Kubo T
Cancer; 1999 Jun; 85(11):2475-84. PubMed ID: 10357421
[TBL] [Abstract][Full Text] [Related]
3. Epithelial markers in thyroid carcinoma: an immunoperoxidase study.
Wilson NW; Pambakian H; Richardson TC; Stokoe MR; Makin CA; Heyderman E
Histopathology; 1986 Aug; 10(8):815-29. PubMed ID: 2428725
[TBL] [Abstract][Full Text] [Related]
4. An immunohistochemical study in thyroid cancer.
Beltrami CA; Barbatelli G; Criante P; Paliaga A; Amadi CE
Appl Pathol; 1987; 5(4):229-45. PubMed ID: 2446641
[TBL] [Abstract][Full Text] [Related]
5. Carcinoembryonic antigen in medullary thyroid carcinoma: an immunohistochemical study applying six novel monoclonal antibodies.
Dasović-Knezević M; Børmer O; Holm R; Høie J; Sobrinho-Simões M; Nesland JM
Mod Pathol; 1989 Nov; 2(6):610-7. PubMed ID: 2587568
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma.
Jakubiak-Wielganowicz M; Kubiak R; Sygut J; Pomorski L; Kordek R
Pol J Pathol; 2003; 54(2):111-5. PubMed ID: 14575419
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
8. [A case with poorly differentiated follicular carcinoma of the thyroid produced and secreted CEA].
Kobayashi K; Yokozawa T; Ito Y; Matsuzuka H; Kuma K; Miyauchi A; Kakudo K
Nihon Geka Gakkai Zasshi; 2003 Jun; 104(6):488-90. PubMed ID: 12854498
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry of thyroid carcinoma--an experience with thyroglobulin and calcitonin.
Kavishwar VS; Phatak AM; Rege JD
Indian J Pathol Microbiol; 1998 Apr; 41(2):163-7. PubMed ID: 9670628
[TBL] [Abstract][Full Text] [Related]
10. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors.
Raphael SJ; McKeown-Eyssen G; Asa SL
Mod Pathol; 1994 Apr; 7(3):295-300. PubMed ID: 7520169
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers for endocrine neoplasms].
Okamoto T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):561-5. PubMed ID: 11329795
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions.
Mitselou A; Vougiouklakis TG; Peschos D; Dallas P; Boumba VA; Agnantis NJ
Anticancer Res; 2002; 22(3):1777-80. PubMed ID: 12168868
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic contribution of HBME-1 and anti-cytokeratin-19 antibodies in thyroid pathology: a retrospective study of 163 cases].
Ziadi S; Trimeche M; Zermani R; Elmay A; Baltagi-Ben Jilani S
Tunis Med; 2005 May; 83(5):274-8. PubMed ID: 16044900
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical study of type-1 blood antigen expressions in thyroid tumors: the significance for papillary carcinomas.
Kamoshida S; Ogane N; Yasuda M; Muramatsu T; Bessho T; Kajiwara H; Osamura RY
Mod Pathol; 2000 Jul; 13(7):736-41. PubMed ID: 10912932
[TBL] [Abstract][Full Text] [Related]
15. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma.
Chiappetta G; Tallini G; De Biasio MC; Manfioletti G; Martinez-Tello FJ; Pentimalli F; de Nigris F; Mastro A; Botti G; Fedele M; Berger N; Santoro M; Giancotti V; Fusco A
Cancer Res; 1998 Sep; 58(18):4193-8. PubMed ID: 9751634
[TBL] [Abstract][Full Text] [Related]
16. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
17. [CD26/dipeptidyl peptidase IV and thyroid peroxidase as molecular markers for differentiated thyroid carcinoma].
Umeki K; Yamamoto I; Maruta J; Aratake Y; Ono I; Uemura Y; Tanaka T; Toyoda K; Kotani T; Noguchi S; Sakamoto F; Konoe K; Ohtaki S
Rinsho Byori; 1996 Jan; 44(1):42-50. PubMed ID: 8691639
[TBL] [Abstract][Full Text] [Related]
18. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
19. [Poorly differentiated carcinoma of the thyroid--immunohistochemical evaluation of p53 and p27 protein expression].
Wierzchowski W; Szybiński P; Nowak W; Nowak K; Szybiński Z; Buziak-Bereza M; Stachura J
Wiad Lek; 2001; 54 Suppl 1():79-87. PubMed ID: 12182066
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
